Clinical trial
An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
NCT00215657 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
- Lead sponsor
- Ferring Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 31, 2003
- Completion date
- March 31, 2006
- Enrollment
- 131 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer